Evidence map›Paper›PMID 40877083›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2025

Neutrophil store-operated Ca

Joe A Wrennall, Matthew Gs Biggart, Charles D Bengtson, M Flori Sassano, Robert Tarran

Abstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joe A WrennallDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, NC, 27599.
Matthew Gs BiggartDivision of Genetic, Environmental and Inhalational Disease, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS, 66103, USA.
Charles D BengtsonDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS, 66103, USA.
M Flori SassanoDivision of Genetic, Environmental and Inhalational Disease, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS, 66103, USA.
Robert TarranDivision of Genetic, Environmental and Inhalational Disease, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS, 66103, USA. Electronic address: rtarran@kumc.edu.

Funding

Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Scott H Randell · 2004 to 2026
$26.5M
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the LungR42AI155107 · NIAID · ELDEC PHARMACEUTICALS, INC. · PI TARRAN, ROBERT · 2020 to 2022
$2.3M
Targeting inflammation to improve rescue of CFTR by modulator therapyK23HL163445 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Charles Bengtson · 2023 to 2026
$693k
Optimizing ELD607 for Delivery by InhalationR61HL173911 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI TARRAN, ROBERT · 2024 to 2024
$543k
NHLBI NIH HHS K23 HL163445NHLBI NIH HHS R61 HL173911NIAID NIH HHS R42 AI155107NIDDK NIH HHS P30 DK065988
6 · The paper itself

Abstract

rationalePeople with cystic fibrosis (pwCF) exhibit chronic and hyperactive neutrophilia which results in a progressive loss of lung function. CF neutrophils have elevated store operated Ca

objectivesTo characterize Orai1/SOCE in neutrophils from pwCF taking ETI, and to evaluate the impact of SOCE inhibition by ELD607 on pwCF neutrophil Ca

methodsPeripheral blood neutrophils were isolated by negative selection. SOCE was characterized using fluorescent approaches. Protein expression was characterized by proteomics and confocal microscopy. Neutrophil degranulation was measured using a multiplex assay. MEASUREMENTS AND MAIN

resultsProteomic analysis revealed major global differences between non-CF and pwCF neutrophils, despite use of ETI. Several proteins involved in SOCE, including Orai1, were significantly elevated in pwCF neutrophils. ELD607 dose-dependently inhibited SOCE, leading to reduced neutrophil degranulation. Ca

conclusionsOur findings highlight SOCE as a novel biomarker of CF lung disease. ELD607 can be used to reduce SOCE and subsequent degranulation in CF neutrophils. We therefore hypothesize that ELD607 may be of benefit in the management of inflammation in pwCF.

Indexed as

CalciumCystic FibrosisNeutrophilsORAI1 ProteinAdolescentAdultAminophenolsBenzodioxolesBiomarkersCalcium SignalingCase-Control StudiesChloride Channel AgonistsDisease ProgressionDrug CombinationsFemaleForced Expiratory VolumeAminophenolsBenzodioxolesBiomarkersCalciumChloride Channel AgonistsDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesIntracellular Calcium-Sensing ProteinsMembrane ProteinsORAI1 ProteinORAI1 protein, humanPyrazolesPyridinesQuinolinesSARAF protein, humanCFTRIcracneutrophil elastaseOrai1

Identifiers

PMID40877083
PMCPMC12998938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.